Corcept Therapeutics price target raised to $150 from $76 at Truist
Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.
Targeted Oncology1d
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades'
Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. META -2.04% Get Free Report is his top pick out of the Mag ...
Corcept's ovarian cancer drug cuts disease progression in study, shares jump
Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...
Brokerages Set AbbVie Inc. (NYSE:ABBV) Target Price at $211.45
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...
Targeted Oncology2d
The Targeted Pulse: Explaining Survivorship Care and Other Positive Developments Across Cancers
Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.
The Healthy @Reader's Digest5d
“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise
A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
CURE5d
Rina-S Generates Antitumor Activity in Heavily Pretreated Ovarian Cancer
Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...
Pharmaceutical Stocks To Consider – March 25th
Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...